Movers and SHAKERS
Monday, November 11, 2019
Q3 2019 Results: Trovagene Continues Progressing
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company's clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Progress Made in Three Clinical Programs. Trovagene has made progress in multiple clinical programs including; initiation of Phase 2 study in acute myeloid leukemia (AML) assessing onvansertib in combination with decitabine, multiple data readouts from three clinical programs including AML, metastatic castration-resistant prostate cancer (mCRPC) and KRAS-mutated metastatic colorectal cancer (mCRC)..
- Third Quarter Results. The company reported total operating expenses of $4.3 million; $2.8 million of R&D expenses and $1.5 million in SG&A expenses. Trovagene has $9.0 million of cash and cash equivalents, as of September 30, 2019. We have updated our model incorporating reported numbers and ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.